Article

Bbarrons.com on 2021-06-18 14:34

Biogen Stock Can Go 'Decisively Higher' on Sales of Alzheimer's Drug2 min read

Piper Sandler analyst Christopher Raymond didn't think the FDA should approve Aduhelm, but he believes sales will be much higher than Wall Street expects.

Wall Street

Related news

BBiogen Is Still a Buy Despite Alzheimer's Drug Concerns, Analyst Says2 min read barrons.com
BBiogen Stock Drops as Results Fall Short. Sales of Alzheimer's Drug Disappoint.3 min read barrons.com
Wall Street
BAlzheimer's Drugs May Be a Big-Pharma Payday. Lilly and Biogen Are Facing Off. 4 min read barrons.com
San Francisco
MOne Alzheimer's drug has failed, but investors are still betting on Biogen and Lilly treatments 2 min read marketwatch.com
Phase 1 , Wall Street
BStreet Shrugs Off FDA's Call for Probe of Alzheimer's Drug Approval3 min read barrons.com
Wall Street
MBeset by challenges with its Alzheimer's disease drug, Biogen pivots3 min read marketwatch.com
Wall Street
MBiogen and Eisai make plans to take another Alzheimer's drug to the FDA3 min read marketwatch.com
Switzerland , Canton of Solothurn , Japan , San Francisco
BBiogen Is Giving Away Its Controversial Alzheimer's Drug: Report 2 min read barrons.com
Florida
BBiogen to Eliminate Alzheimer's Drug Infrastructure, Search for New CEO1 min read barrons.com
BBiogen in Pole Position After Roche's Alzheimer's Drug Disappoints3 min read barrons.com
Switzerland
BBiogen Stock Is Tumbling Because Its Alzheimer's Drug Rollout Isn't Going So Well2 min read barrons.com
Massachusetts , Cambridge , Stock Island
BBiogen Says EU Regulator Takes 'Negative Opinion' on Its Alzheimer's Drug1 min read barrons.com
Tokyo Prefecture , Stock Island
BRoche Sinks as Alzheimer's Drug Disappoints. Biogen is Gaining. 1 min read barrons.com
Switzerland
BBiogen, Eisai's Alzheimer's Data Confirm Benefit, But Questions Loom2 min read barrons.com
BBiogen Stock Tumbles After EU Regulator Has Doubts on Controversial Alzheimer's Therapy1 min read barrons.com
BRoche Stock Could Be an Alzheimer's Winner3 min read barrons.com
Switzerland
MBiogen, under pressure, tells investors it 'stands by' the FDA review process for its Alzheimer's drug2 min read marketwatch.com
New York , Ohio
BBiogen Sold $1.6M of Aduhelm in Weeks After Approval. Earnings Were Strong.2 min read barrons.com
BBiogen Stock Is Down on a Report That Few Have Received Its New Alzheimer's Therapy3 min read barrons.com
Stock Island
MRegulatory approval is next: Mizuho lifts Biogen to buy on news of Alzheimer's drug success as shares soar2 min read marketwatch.com
Tokyo Prefecture